Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Nivolumab/Ipilimumab Doubles Intracranial Response in Melanoma Brain Mets

Jason Harris
Published: Thursday, Apr 05, 2018

Georgina V. Long, BSc, PhD, MBBS

Georgina V. Long, BSc, PhD, MBBS
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an intracranial response of 46% in melanoma patients with asymptomatic, untreated brain metastases. The intracranial response rate (ICR) with nivolumab monotherapy was 20%.

There were no deaths attributed to the study treatment. Nine (26%) patients in cohort A, one (4%) in cohort B, and 1 (6%) in cohort C discontinued study treatment due to AEs.
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomised phase 2 study [published online March 27, 2018]. Lancet Oncol. doi: 10.1016/ S1470-2045(18)30139-6.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication